This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

46/100

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Lewy body dementia

Topic: Amyloid, tau and blood-test diagnosis

= 0.205; p = 0.651); and between typical (21%) and atypical (11%) subgroups (Fisher's test, p = 0.184). However, in DV+ patients, symptom onset occurred 8.0 years earlier than in DV- patients (95% CI [-14, -3.0]; p = 0.005), with a median onset age of 58 years (IQR: 15). A DV could favor early-onset AD/FTD, but may not affect susceptibility to typical and atypical variants of AD/FTD. The underlying neurophysiological processes involved require future investigation, with implications for precision medicine and individualized treatment strategies. STUDY REGISTRATION NUMBERS: RnIPH 2023-71 and Research Ethics Committee file No. 2023_765.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Siguier, P. L. M., Planton, M., Pages, B., Gérard, F., Rafiq, M., Wolfrum, M., et al. (2025). Neurodevelopmental Vulnerability in Alzheimer's Disease and Frontotemporal Dementia. European Journal of Neurology. https://doi.org/10.1111/ene.70322

Vancouver

Siguier PLM, Planton M, Pages B, Gérard F, Rafiq M, Wolfrum M, et al. Neurodevelopmental Vulnerability in Alzheimer's Disease and Frontotemporal Dementia. European Journal of Neurology. 2025. doi:10.1111/ene.70322. PMID: 40757649.

BibTeX

@article{siguier2025-40757649,
  author  = {Siguier, Perrine Laury Marie and Planton, Mélanie and Pages, Bérengère and Gérard, Fleur and Rafiq, Marie and Wolfrum, Marie and Archambault, Ombeline and Damour, Anise and others},
  title   = {{Neurodevelopmental Vulnerability in Alzheimer's Disease and Frontotemporal Dementia}},
  journal = {European Journal of Neurology},
  year    = {2025},
  doi     = {10.1111/ene.70322},
  pmid    = {40757649},
  url     = {https://doi.org/10.1111/ene.70322}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

= 0.205; p = 0.651); and between typical (21%) and atypical (11%) subgroups (Fisher's test, p = 0.184).
However, in DV+ patients, symptom onset occurred 8.0 years earlier than in DV- patients (95% CI [-14, -3.0]; p = 0.005), with a median onset age of 58 years (IQR: 15).
A DV could favor early-onset AD/FTD, but may not affect susceptibility to typical and atypical variants of AD/FTD.
The underlying neurophysiological processes involved require future investigation, with implications for precision medicine and individualized treatment strategies.
STUDY REGISTRATION NUMBERS: RnIPH 2023-71 and Research Ethics Committee file No. 2023_765.

Why it matters

This study found that a developmental variant could favor early-onset AD/FTD, with symptom onset occurring 8.0 years earlier, but it may not affect susceptibility to typical and atypical variants. The underlying processes require future investigation, so no treatment or prevention is available.

Study details

Participants84
Evidence strengthLow

How this study scored 46/100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (European Journal of Neurology)
Journal's citation record	2 / 4	European Journal of Neurology: journal h-index 181 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	1 / 4	84 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 4 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	1.3 citations a year over 3 year(s) since 2025
Impact for its field and year	2 / 6	Cited 2.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	1 / 4	Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Jérémie Pariente: h-index 52 (OpenAlex, whole career)
Institution's track record	3 / 3	Centre National de la Recherche Scientifique: institution h-index 2,511 (OpenAlex)
Multi-centre collaboration	3 / 3	OpenAlex lists 19 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40757649)
Free to read	2 / 2	Free to read
Total	46 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Lewy body dementia

Also tagged “bodies”

1,017 studies in the library carry the topic tag “bodies”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Similar studies

More on Lewy body dementia

See all studies in Lewy body dementia →